REM Sleep Behavior Disorder (RBD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by the absence of muscle atonia during REM sleep, known as REM sleep without atonia (RSWA), and the occurrence of abnormal behaviors during REM sleep, often resembling actions from dreams that can result in physical harm. RBD can be classified as either idiopathic RBD or symptomatic RBD, the latter being associated with the use of antidepressant medication or neurological disorders, particularly α-synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and narcolepsy type 1. The underlying cause of RBD is the failure to inhibit spinal motor neurons during REM sleep. A significant correlation has been established between RBD and the subsequent development of neurodegenerative disorders. Neurodegenerative diseases characterized by alpha-synuclein-positive intracellular inclusions, including parkinsonism, Lewy body dementia, and multiple system atrophy, are associated with α-synucleinopathies. The nuclei in the pons play a crucial role in controlling REM sleep, and lesions in this region can lead to the development of synucleinopathies and RBD. Normal REM sleep involves two systems: one responsible for generating muscle atonia and the other for suppressing motor-skeletal activity. Muscle atonia is achieved through active inhibition by medullary neurons, while locomotion involves input from the forebrain, and the thalamus influences spinal motor neurons. Several brainstem pontine regions, including the peri-locus coeruleus region, pedunculopontine nucleus (PPN), and laterodorsal tegmental nucleus (LDTN), have been implicated in the pathophysiology of RBD. Supra-spinal processes control the mechanism of REM atonia. During REM sleep, pontine nuclei stimulate medullary neurons, sending inhibitory signals to spinal alpha motor neurons, leading to hyperpolarization and muscle atonia. The loss of inhibition of these neurons results in muscle activity during the REM stage of sleep. The differential diagnosis may include RBD, obstructive sleep apnea, nightmares, nocturnal panic attacks, seizures, and non-REM parasomnias such as night terrors, sleepwalking, or confusional arousals. The prognosis of RBD depends on its underlying cause. In idiopathic cases, symptoms can be managed with medication. However, the primary disease causing RBD influences the prognosis in secondary cases.
- RBD is a relatively rare condition, affecting approximately 1% of the general population in the United States and around 2% of individuals aged 50 years or older. Among younger adults (under 40 years old), RBD most commonly occurs in the context of antidepressant medication usage or narcolepsy.
Thelansis’s “REM Sleep Behavior Disorder (RBD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential REM Sleep Behavior Disorder (RBD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of REM Sleep Behavior Disorder (RBD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
REM Sleep Behavior Disorder (RBD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment